The European Commission approves an eight-week regimen for AbbVie's (NYSE:ABBV) MAVIRET (glecaprevir/pibrentasvir) for previously untreated patients with hepatitis C virus (HCV) genotypes 1,2,4,5 or 6 infection with compensated cirrhosis. It was previously approved as a 12-week regimen in these patients.
MAVIRET was first approved in Europe two years ago as an eight-week regimen for treatment-naive HCV patients without cirrhosis.
Related ticker: Enanta Pharmaceuticals (NASDAQ:ENTA)
Subscribe for full text news in your inbox